Coronary arteries come in a range of sizes, and treating the narrowest end of that range brings its own set of technical considerations. Small vessel coronary disease generally refers to disease occurring in vessels toward the smaller end of the treatable diameter range, sometimes discussed at a textbook level as reference diameters around 2.25 to 2.5 mm. Because of the limited space available for a device and the biological behavior of smaller arteries, treating small vessel disease has historically presented distinct challenges compared to larger-vessel PCI, and it remains an area of ongoing device development and clinical discussion.
Why Are Smaller Coronary Vessels More Challenging to Treat?
Smaller-diameter vessels leave less room for error during stent deployment, and any degree of vessel injury, plaque shift, or incomplete stent expansion has proportionally more impact on the remaining lumen than it would in a larger artery. Smaller vessels have also been discussed in the literature as being associated with a comparatively higher rate of restenosis, or renarrowing, following stenting relative to larger vessels, a pattern generally attributed to the smaller absolute lumen area available after treatment. Deliverability is also a practical consideration: navigating a stent through tortuous or calcified anatomy to reach a small, often more distal vessel can be technically demanding, which places added importance on catheter and stent platform design.
What Design Features Matter for Small Vessel Stents?
Because deliverability and vessel trauma are central concerns in small vessel PCI, stent platform characteristics such as strut thickness and overall flexibility are frequently discussed by manufacturers and clinicians in this context. Thinner struts are generally associated with a lower profile device that can navigate tighter and more tortuous anatomy with less vessel trauma during passage. INVAMED's ATLAS Drug Eluting Coronary Stent System (Cobalt Chromium) is manufactured on a thin-strut, 60 µm cobalt-chromium L605 alloy platform, which the manufacturer describes as supporting durable radial strength and trackability, including in complex and calcified lesions. As with any coronary stent, specific size availability, indications, and deployment parameters should be confirmed through the product's Instructions for Use (IFU), and appropriateness for an individual small vessel case is determined by the treating physician. More detail on this device is available on the ATLAS Drug Eluting Coronary Stent System product page.
Are Drug-Coated Balloons an Alternative to Stenting in Small Vessels?
Drug-coated balloons (DCBs) represent an alternative approach that some physicians consider for small vessel disease. Rather than leaving a permanent stent structure in the vessel, a DCB delivers an antiproliferative drug coating to the vessel wall via balloon inflation alone, without a stent scaffold left behind. This approach is discussed in the literature as a potential option in certain small vessel scenarios, though it is not considered universally superior or inferior to drug-eluting stenting; the decision between a stent-based and balloon-based approach for a small vessel depends on the specific lesion characteristics, vessel behavior after initial balloon dilation, and the judgment of the treating interventional cardiologist.
How Is Treatment Strategy Determined for Small Vessel Disease?
Because small vessel anatomy varies considerably between patients and even between vessels in the same patient, there is no single default strategy. Operators generally weigh vessel size, calcification, lesion length, and tortuosity when selecting between stenting and balloon-based approaches. For a broader look at coronary devices used across vessel sizes, see the INVAMED coronary artery disease and cardiac interventions category.
Is a drug-coated balloon always better than a stent for small vessels?
No. Neither approach is considered universally superior; each has different characteristics, and selection depends on the specific lesion, vessel response to initial dilation, and physician judgment. A qualified interventional cardiologist determines the most appropriate approach for an individual case.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.